CMPX - NASDAQ

Compass Therapeutics, Inc.

Compass Therapeutics, Inc.

CMPXยทNASDAQ

$2.13

+2.4%
HealthcareBiotechnology

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$294.55M
EPS-0.4200
P/E Ratio-5.07
Earnings Date08/10/2026
Compass Therapeutics, Inc.

Compass Therapeutics, Inc. Fair Value Envelope

CMPX ยท NASDAQ

Our analysis suggests that CMPX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.13, this represents a potential HIDDEN relative to our calculated worth for Compass Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $2.13

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$210.7M
+ Cash & Equivalents$30.6M
Firm Value-$180.1M
- Debt$9.8M
Equity Value-$189.9M
/ Shares Outstanding138,286,301B
DCF Value-$1
OVERVALUED BY 164%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$44.5M
-$40.2M
-$36.4M
-$33.0M
-$29.8M
-$27.0M
-$24.4M
-$22.1M
-$20.0M
-$18.1M
Maintenance CapEx
-$4.5K
-$4.1K
-$3.7K
-$3.4K
-$3.0K
-$2.7K
-$2.5K
-$2.2K
-$2.0K
-$1.8K
Owner Earnings
-$44.5M
-$40.2M
-$36.4M
-$33.0M
-$29.8M
-$27.0M
-$24.4M
-$22.1M
-$20.0M
-$18.1M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$41.2M
-$34.5M
-$28.9M
-$24.2M
-$20.3M
-$17.0M
-$14.2M
-$11.9M
-$10.0M
-$8.4M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your CMPX research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.